Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy

Table 4 Univariate and multivariate analyses of clinical factors or cytokines for failure-free survival - outfield-intrahepatic failure-free survival

	Univariate		Multivariate
	P value	RR (95%CI)	P value	RR (95%CI)
Sex	0.387	1.539 (0.579-4.086)
Age	0.834	0.996 (0.959-1.035)
Stage	0.601	0.834 (0.423-1.646)
BCLC	0.383	1.210 (0.788-1.859)
Size	0.534	0.974 (0.898-1.058)
PVT	0.326	1.433 (0.699-2.940)
LN metastasis	0.387	0.530 (0.126-2.230)
Multiplicity	0.303	1.464 (0.709-3.021)
AFP	0.649	1.000 (0.999-1.002)
PIVKA-II	0.920	1.002 (0.963-1.043)
Pre-RT treatment	0.745	1.126 (0.550-2.307)
Baseline IL-1	0.573	1.015 (0.964-1.069)
Baseline IL-6	0.271	0.950 (0.985-1.004)
Baseline IL-8	0.942	1.000 (0.998-1.002)
Baseline IL-10	0.026	0.830 (0.705-0.978)	0.026	0.830 (0.705-0.978)
Baseline IL-12	0.197	0.959 (0.901-1.022)
Baseline TNF-α	0.240	0.951 (0.876-1.034)

Age, size, AFP, PIVKA-II, and baseline cytokine levels were analyzed as continuous variables using the Cox hazard ratio model. BCLC: Barcelona Clinic Liver Cancer; PVT: Portal vein thrombosis; LN: Lymph node; AFP: α-fetoprotein; PIVKA-II: Prothrombin induced by vitamin K absence-II; RT: Radiotherapy; IL: Interleukin; TNF: Tumor necrosis factor.